Moderna GAAP EPS of $2.53 misses by $0.66, revenue of $3.36B misses by $170M
Moderna press release  (NASDAQ:MRNA): Q3  GAAP EPS of $2.53  misses by $0.66.
Revenue of $3.36B (-32.4% Y/Y)  misses by $170M.
Total revenue for the third quarter of 2022 was $3.4 billion compared to $5.0 billion in the same period in 2021, mainly due to a decline in sales of the Company's COVID-19 vaccines.Â 
Revenue from advance purchase agreements for anticipated delivery in 2022 expected to be $18 to $19 billion, following delay of certain deliveries into 2023 due to short-term supply constraints
Completed $3 billion share repurchase plan announced in February 2022; commenced August 2022 $3 billion share repurchase program
Â 
Â